Publication: 4742

Publication: 4742

A Randomized Phase II Study of Daratumumab, Lenalidomide, Ixazomib, and Dexamethasone in Transplant-Ineligible or Deferred Patients with Newly Diagnosed Multiple Myeloma: Alliance Foundation Trial 41 (AFT-41)

Google Scholar

Citation:

Meeting Instance:: ASH 2025
Year:: 2025
Type:: Abstract
Sub type:
Funding:: AFT
Endpoint:: Primary
Analysis:: Preliminary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen, Takeda, Celgene
Grants:

Corr. Author:
Authors:: Andrew Yee Betsy O'Donnell Omar Nadeem Tanya Wildes Tondre Buck Sascha Tuchman Krishna Ghimire Sarah Sinclair Garth Nelson Catherine Stewart Paul Richardson Saad Usmani Noopur Raje

Networks:: LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, ME040, NE003, NY141, UPSTATE

Study: AFT-41
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: